Formulated for covid-19 to manage viral load and support infection resolution in high-risk patients.
Mechanism of Action
Molnupiravir is converted into an active metabolite that is used by the viral RNA-dependent RNA polymerase. This causes lethal mutagenesis, leading to the accumulation of errors in the viral genome.
Route of Administration
Oral
Onset Time
1–3 days
Duration
5 days (treatment course)
Contraindications
Pregnancy, Hypersensitivity to molnupiravir
Severe Adverse Events
Severe hypersensitivity, Angioedema — requires immediate medical attention
Common Side Effects
Diarrhea, Nausea, Dizziness
Uncommon Side Effects
Headache, Rash, Urticaria
Drug Interactions
Alcohol
Pregnancy Safety Warnings
FDA Category D: High risk of fetal harm; contraindicated. Breastfeeding: Not recommended during and for 4 days after treatment.
Age Restrictions
Not recommended for patients under 18 years of age due to potential bone growth effects.
Information related to Molnunat is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
